|
Business
Zacks Analyst Interview Highlights: Abbott Labs, Bristol-Myers, General Dynamics, Smith International and CSX Corp.
© Business Wire 2008
2008-10-07 12:27:02 - - Zacks.com releases the latest Analyst Interview. Today's interview is with Senior Market Analyst Charles Rotblut, who discusses Abbott Labs (NYSE: ABT), Bristol-Myers (NYSE: BMY), General Dynamics (NYSE: GD), Smith International (NYSE: SII) and CSX Corp. (NYSE: CSX).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:
|
|
| target="_blank">at.zacks.com/?id=2678.
So, when will investors feel safe investing?
Over the short-term, there is a real risk that stocks could fall even further. The selling is indiscriminate and good stocks are falling in price, but at some point buyers will step back in and pick up bargains. Therefore, investors should consider dollar-cost averaging. This means buying shares in a company over a period of months instead of all at once. Commissions are cheap enough that if you can build your position without incurring large transaction costs.
What stocks should investors look at?
In the current market environment, I would suggest going towards larger, more established companies.
The big pharmaceuticals, such as Abbott Labs (NYSE: ABT) and Bristol-Myers (NYSE: BMY), are less economically sensitive because people need to keep taking their medication. General Dynamics (NYSE: GD) does a lot of business with the government, and the next president is unlikely to cut back on defense spending. Smith International (NYSE: SII) makes drilling equipment for oil companies. It is very shareholder-friendly and will do well as long as oil stays above $65 per barrel. I also like CSX Corp. (NYSE: CSX), which is a railroad. The company recently raised its earnings guidance through 2010 - a bullish sign.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks Profit from the Pros e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting at.zacks.com/?id=2679.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at at.zacks.com/?id=4581.
Visit www.zacks.com/performance for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks.com
Mark Vickery
Zacks Web Content Editor
312-265-9380
Visit: www.zacks.com
|
| Disclaimer:
(c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
|
 |
|
